Prostate Cancer: Advances in Radiation Oncology, Molecular Biology, and Future Treatment Strategies
Document Type
Book ChapterPublication Date
2022-09-12Keywords
clinical process improvement for prostate cancermodern care for the prostate patient
patient outcome in prostate cancer
radiation therapy for prostate cancer
treatment strategies for prostate cancer
Metadata
Show full item recordAbstract
Prostate cancer remains an important health problem worldwide affecting one in every six men including members of vulnerable communities. Although successful treatments have been delivered to men affected with the disease resulting in improved patient outcome, process improvements including therapy titration and augmentation are needed to optimize tumor control and limit normal tissue injury from therapy. In this chapter, we describe current management strategies for optimal patient care with radiation therapy and opportunities for improvement of care moving forward with applied science to apply therapy in a strategic manner, potentially improving care and outcome for patients treated for this disease.Source
Wang T, Lewis B, Ruscetti M, Mittal K, Wang MJ, Sokoloff M, Ding L, Bishop-Jodoin M, FitzGerald TJ. Prostate Cancer: Advances in Radiation Oncology, Molecular Biology, and Future Treatment Strategies. In: Barber N, Ali A, editors. Urologic Cancers [Internet]. Brisbane (AU): Exon Publications; 2022 Sep 12. Chapter 13. PMID: 36343136.DOI
10.36255/exon-publications-urologic-cancers-prostate-cancer-radiation-oncologyPermanent Link to this Item
http://hdl.handle.net/20.500.14038/51356Rights
Copyright: The Authors. The authors confirm that the materials included in this chapter do not violate copyright laws. Where relevant, appropriate permissions have been obtained from the original copyright holder(s), and all original sources have been appropriately acknowledged or referenced. Licence: This open access article is licenced under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0) https://creativecommons.org/licenses/by-nc/4.0/; Attribution-NonCommercial 4.0 InternationalDistribution License
http://creativecommons.org/licenses/by-nc/4.0/Scopus Count
Collections
The following license files are associated with this item:
- Creative Commons
Except where otherwise noted, this item's license is described as Copyright: The Authors.
The authors confirm that the materials included in this chapter do not violate copyright laws. Where relevant, appropriate permissions have been obtained from the original copyright holder(s), and all original sources have been appropriately acknowledged or referenced.
Licence: This open access article is licenced under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0) https://creativecommons.org/licenses/by-nc/4.0/
Related items
Showing items related by title, author, creator and subject.
-
PTEN loss in biopsy tissue predicts poor clinical outcomes in prostate cancerOBJECTIVES: To determine whether PTEN status in prostate biopsy represents a predictor of intermediate and long-term oncological outcomes after radical prostatectomy, and whether PTEN status predicts response to androgen deprivation therapy. METHODS: In a retrospective analysis of 77 men treated by radical prostatectomy who underwent diagnostic biopsy between 1992-2006, biopsy samples were stained for PTEN expression by the PREZEON assay with > 10% staining reported as positive. Cox proportional hazards and log-rank models were used to assess the correlation between PTEN loss and clinical outcomes. RESULTS: During a median follow-up period after radical prostatectomy of 8.8 years, 39 men (51%) developed biochemical recurrence, four (5%) had castration-resistant prostate cancer, two (3%) had metastasis and two (3%) died from prostate cancer. PTEN loss was not significantly associated with biochemical recurrence (hazard ratio 2.1, 95% confidence interval 0.9-5.1, P = 0.10), but significantly predicted increased risk of castration-resistant prostate cancer, metastasis and prostate cancer-specific mortality (all log-rank, P < 0.0001), and time from androgen deprivation therapy to castration-resistant prostate cancer (log-rank, P = 0.003). No patient without PTEN loss developed metastases or died from prostate cancer. CONCLUSIONS: PTEN loss at the time of biopsy seems to predict time to development of metastasis, prostate cancer-specific mortality and, for the first time, castration-resistant prostate cancer and response to androgen deprivation therapy after radical prostatectomy. If confirmed by larger studies, this would support the use of PTEN loss as an early marker of aggressive prostate cancer.
-
UMass PCORI PSA decision aid [English]This is a presentation developed as a decision aid to help consumers understand the May 2012 recommendations of the US Preventive Services Task Force against routine prostate cancer (PSA) screening and why that might be the right choice for them. This decision aid was produced in 2013-2014 under research contract 1IP2PI000633 from the Patient-Centered Outcomes Research Institute (PCORI) to the University of Massachusetts Medical School by personnel from: The University of Massachusetts Medical School, the University of Massachusetts Boston, and the Central Massachusetts Area Health Education Center.
-
Trends in breast and prostate cancer screening and diagnostic procedures during the COVID-19 pandemic in central MassachusettsPurpose: We calculated rates of breast and prostate cancer screening and diagnostic procedures performed during the COVID-19 pandemic through December 2021 compared to the same months in 2019 in a large healthcare provider group in central Massachusetts. Methods: We included active patients of the provider group between January 2019 and December 2021 aged 30-85 years. Monthly rates of screening mammography and digital breast tomosynthesis, breast MRI, total prostate specific antigen (PSA), and breast or prostate biopsy per 1,000 people were compared by year overall, by age, and race/ethnicity. Completed procedures were identified by relevant codes in electronic health record data. Results: Rates of screening mammography, tomosynthesis, and PSA testing reached the lowest levels in April-May 2020. Breast cancer screening rates decreased 43% in March and 99% in April and May 2020, compared to 2019. Breast cancer screening rates increased gradually beginning in June 2020 through 2021, although more slowly in Black and Hispanic women and in women aged 75-85. PSA testing rates decreased 34% in March, 78% in April, and 53% in May 2020, but rebounded to pre-pandemic levels by June 2020; trends were similar across groups defined by age and race/ethnicity. Conclusion: The observed decline in two common screening procedures during the COVID-19 pandemic reflects the impact of the pandemic on cancer early detection and signals potential downstream effects on the prognosis of delayed cancer diagnoses. The slower rate of return for breast cancer screening procedures in certain subgroups should be investigated to ensure all women return for routine screenings.